Article: Fosamax(R) Increased Bone Mass in Men at Risk for Osteoporosis Due to Chronic Glucocorticoid Use.

SAN DIEGO, Nov. 9 /PRNewswire/ -- New data presented today at the annual meeting of the American College of Rheumatology showed the investigational use of Fosamax(R) (alendronate sodium) in men stopped bone loss and increased bone mineral density (BMD) at the spine and hip, two common sites of osteoporotic fracture. The men in the study all were at risk of osteoporosis and future fracture due to chronic use of glucocorticoids (commonly referred to as corticosteroids, or steroids).

"Previous studies have shown Fosamax to be effective in treating and preventing osteoporosis in postmenopausal women. These new data are important because they looked at the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!